Beam Therapeutics Stock Surge#
Beam Therapeutics Inc. (NASDAQ:BEAM) saw its stock price jump by 8% on Tuesday after the company released encouraging clinical data from its ongoing Phase 1/2 trial of BEAM-302, a treatment for alpha-1 antitrypsin deficiency (AATD).
Trial Results Overview#
The latest findings revealed that a 60 mg dose of BEAM-302 achieved a mean steady-state total AAT level of 16.1 µM. Notably, all patients maintained AAT levels above the protective threshold of 11 µM for up to 12 months. Additionally, 94% of the total AAT was corrected M-AAT, with an 84% reduction in the harmful mutant Z-AAT following treatment.
About BEAM-302#
BEAM-302 is a specialized formulation designed to target the liver and directly correct the genetic mutation responsible for severe AATD using a technique called base editing. The ongoing trial is open-label, meaning both the researchers and participants know what treatment is being administered, and it aims to assess the safety, tolerability, and effectiveness of the therapy.
Safety Profile and Future Plans#
As of the latest data cutoff on February 10, 29 patients have been treated with BEAM-302, with follow-ups extending up to 18 months. The results indicate a well-tolerated safety profile, with mild to moderate adverse events reported and no serious adverse events or dose-limiting toxicities noted. The company has determined that 60 mg is the optimal dose based on safety and efficacy data, and plans to initiate a global pivotal cohort in the second half of 2026 to support potential accelerated approval.
Additional Observations#
Interestingly, during a respiratory infection, one patient in the 60 mg group exhibited a significant increase in total AAT levels, rising from 15.9 µM to 29.5 µM, while maintaining a consistent composition of 95% M-AAT. In patients with AATD-related liver disease, both 30 mg and 60 mg doses of BEAM-302 showed consistent efficacy similar to that observed in patients without liver disease.